OncoMatch/Clinical Trials/NCT05880667
Adaptive Radiation for Abdominopelvic Metastases
Is NCT05880667 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies non-drug interventions for neoplasm - soft tissue pelvis malignant secondary.
Single arm Phase I trial of adaptive stereotactic body radiation (SBRT) for abdominopelvic metastases. Adaptive SBRT will allow for escalation of the prescription dose and target coverage while maintaining grade 3+ toxicity no greater than 10%. Subjects with metastatic cancer to the abdomen or pelvis requiring local control or palliation will be enrolled.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
Exception: Prior radiotherapy to non-target sites is allowed.
Subjects must not have had prior radiotherapy to any target metastatic lesion. Prior radiotherapy to non-target sites is allowed.
Lab requirements
Blood counts
absolute neutrophil count > 1,500/mcl; platelets > 100,000/mcl
Kidney function
creatinine < 1.5x uln or creatinine clearance ≥ 50 ml/min/1.73 m2 for subjects with creatinine levels above institutional normal
Liver function
total bilirubin < 2 mg/dl; ast/alt (sgot/sgpt) < 5x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Fox Chase Cancer Center · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05880667 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages